

Ibrutinib for treating relapsed or refractory mantle cell lymphoma

Information for the public

Published: 31 January 2018

www.nice.org.uk

Ibrutinib is available on the NHS. It is a possible treatment for mantle cell lymphoma that has come back or didn't respond to the first treatment tried, in adults.

If you are not eligible for ibrutinib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Macmillan](#), 0808 808 0000
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [Lymphoma Association](#), 0808 808 5555
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0808 2080 888
- [Leukaemia Care](#), 08088 010 444

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2809-5